Pituitary adenylate cyclase activating polypeptide and migraine

Annals of Clinical and Translational Neurology

Volumn 1, Issue 12, 2014, Pages 1036-1040

  Zagami, Alessandro S ^a   Edvinsson, Lars ^b   Goadsby, Peter J ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; SUMATRIPTAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; FEMALE; HEART RATE; HUMAN; ID50; IMMUNOREACTIVITY; MALE; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SUPERIOR SAGITTAL SINUS;

EID: 84929476563     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.113     Document Type: Article

References (25)

1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197–2223.
2. Akerman S, Holland P, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12:570–584.
3. Goadsby PJ, Sprenger T. Current practice and future directions in the management of migraine: acute and preventive. Lancet Neurol 2010;9:285–298.
4. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668–1675.
5. Goadsby PJ. Therapeutic prospects for migraine: can paradise be regained? Ann Neurol 2013;74:423–434.
6. Uddman R, Tajti J, Hou M, et al. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002;22:112–116.
7. Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009;132:16–25.
8. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16:69–75.
9. Zagami AS, Edvinsson L, Hoskin KL, Goadsby PJ. Stimulation of the superior sagittal sinus causes extracranial release of PACAP. Cephalalgia 1995;15(suppl 14):109.
10. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991;114:1001–1011.
11. Headache Classification Committee of The International Headache Society. The international classification of headache disorders (second edition). Cephalalgia 2004;24(suppl 1):1–160.
12. Grunditz T, Ekman R, Hakanson R, et al. Calcitonin gene-related peptide in thyroid nerve fibres and C cells. Effects on thyroid hormone secretion and response to hypercalcaemia. Endocrinology 1986;119:2313–2324.
13. Zhang Y, Malmberg AB, Yaksh TL, et al. Capsaicin-evoked release of pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide (CGRP) from rat spinal cord in vivo. Regul Pept 1997 Mar 26;69:83–87.
14. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:761–766.
15. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104–1110.
16. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept 1992;37:287–303.
17. Harmar AJ, Fahrenkrug J, Gozes I, et al. IUPHAR reviews 1: pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Br J Pharmacol 2012;166:4–17.
18. Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 2012 Jan;32:140–149.
19. Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilatation but does not induce migraine. Cephalalgia 2008;28:226–236.
20. Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013;33:1085–1095.
21. Csati A, Tajti J, Kuris A, et al. Distribution of vasoactive intestinal polypeptide, pituitary adenylate cyclase activating peptide, nitric oxide synthase and their receptors in human and rat sphenopalatine ganglion. Neuroscience 2012;202:158–168.
22. Akerman S, Goadsby PJ. VPAC1 and PAC1 receptor antagonists inhibit activation of the parasympathetic outflow to the cranial vasculature to prevent atuonomic responses and neuronal firing in the trigeminocervical complex. Cephalalgia 2009;29(suppl 1):130.
23. Markovics A, Kormos V, Gaszner B, et al. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol Dis 2012;45:633–644.
24. Robert C, Bourgeais L, Arreto CD, et al. Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J Neurosci 2013 May 15;33:8827–8840.
25. Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin triggered migraine attacks. Brain 2014;137:232–242.